/C O R R E C T I O N -- Scitex Corporation Ltd./

Name	Symbol	Market	Type
Global X Scientific Beta Asia ex Japan ETF	AMEX:SCIX	AMEX	Exchange Traded Fund

	Price Change	% Change	Price	High Price	Low Price	Open Price	Traded	Last Trade
	0.00	0.00%	21.115				0	01:00:00

Global X Scientific Beta... (AMEX:SCIX)
Historical Stock Chart

From Jun 2019 to Jun 2024

Click Here for more Global X Scientific Beta... Charts.

/C O R R E C T I O N -- Scitex Corporation Ltd./ With respect to the news release, "Scitex Announces Fourth Quarter and Full Year 2004 Results" issued on 2 Mar 2005 22:30 GMT, by Scitex Corporation Ltd. (NASDAQ:SCIX)(TASE:SCIX) over PR Newswire, we are advised by a representative of the company as follows: that the financial tables attached to its March 2, 2005, press release should be replaced with the attached financial tables. The tables attached to the March 2, 2005, press release inadvertently reflected under 2003 sales and marketing expenses amounts that are now classified as costs of revenues. Complete, corrected tables follow: SCITEX CORPORATION LTD. (AN ISRAELI COMPANY) AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME (U.S. Dollars in thousands, except per share data) Quarter ended Dec. 31, Year ended Dec. 31, 2004 2003 2004 2003 (Unaudited) (Unaudited) (Audited) (Audited) Revenues Sales 21,252 16,954 78,418 60,653 Services & Supplies 14,242 11,586 49,767 42,227 Total revenues 35,494 28,540 128,185 102,880 Cost of revenues Cost of sales 12,203 9,933 44,132 36,062 Cost of Services and Supplies 7,194 7,002 26,935 27,150 Total cost of revenues 19,397 16,935 71,067 63,212 Gross profit 16,097 11,605 57,118 39,668 Expenses Sales and marketing 5,063 3,430 19,990 15,322 General and administrative 4,510 3,927 16,614 15,147 Research and development, net 3,955 2,935 12,449 11,070 Amortization of other intangible assets 1,556 1,434 6,137 5,871 Impairment of other intangible assets 5,625 2,967 5,235 2,967 Restructuring charges 383 1,590 Operating loss (4,612) (3,471) (3,307) (12,299) Financial Income (expense) - net (602) 328 (276) (2,651) Other income (expenses) - net 213 (68) 470 787 Loss before taxes on income (5,001) (3,211) (3,113) (14,163) Taxes on income 1,220 (814) 67 (2,402) (3,781) (2,397) (3,046) (16,565) Share in losses of associated companies (357) (1,521) (1,418) (5,637) Minority interests in a subsidiary 1,239 440 71 3,546 Net loss from continuing operations (2,899) (3,478) (4,393) (18,656) Net Income from discontinued operations 0 11,494 51,646 20,043 Net income (loss) (2,899) 8,016 47,253 1,387 Earnings (loss) per share - basic & diluted Continuing operations ($0.08) ($0.08) ($0.11) ($0.43) Discontinued operations $0.00 $0.27 $1.28 $0.46 ($0.08) $0.19 $1.17 $0.03 Weighted average number of shares used in computation of EPS (in thousands) - basic and diluted 38,066 43,018 40,336 43,018 CONSOLIDATED BALANCE SHEETS (U.S. Dollars in thousands) December 31 December 31 2004 2003 (Audited) (Audited) Assets Current assets: Cash and cash equivalents 85,892 56,761 Short-term investments 56,693 8,235 Restricted deposit 18,000 18,262 Total cash and short-term investments 160,585 83,258 Trade receivables 33,585 31,279 Other receivables 8,127 7,102 Inventories 36,726 22,575 Current Assets of discontinued operation 161,602 Total current asssets 239,023 305,816 Investments and other non-current assets 4,987 6,669 Restricted deposit 5,000 0 Property and equipment - net 9,147 9,204 Goodwill and other intangible assets - net 15,996 23,499 Non-Current Assets of discontinued operation 48,897 274,153 394,085 Liabilities and Shareholders' Equity Current liabilities: Short term bank credit 30,755 49,251 Current maturities of long -term loans 3,557 2,602 Trade payables 21,877 14,505 Accrued and other liabilities 40,200 47,466 Current liabilities related to discontinued operation 2,193 31,935 Total current liabilities 98,582 145,759 Long-term liabilities: Loans from banks, net of current maturities 8,802 6,623 Other 6,718 6,645 Long-term liabilities related to discontinued operation 5,431 Total long-term liabilities 15,520 18,699 Long-term loans from related parties convertible into shares of subsidiary 1,551 756 Minority interest 4,226 4,173 Shareholders' equity: Share capital 6,205 6,205 Capital surplus 278,812 368,104 Deferred stock compensation (517) Accumulated other comprehensive loss (327) (552) Accumulated deficit (97,599) (144,852) Treasury shares, at cost (32,300) (4,207) 154,274 224,698 274,153 394,085 Scitex Vision Ltd. US Dollar in Thousands Three months ended Year December 31 December 31 2004 2003 2004 2003 Unaudited Unaudited Audited Audited Revenues Sales 21,252 16,954 78,418 60,653 Services & Supplies 14,242 11,586 49,767 42,227 Total Revenues 35,494 28,540 128,185 102,880 Gross Profit 16,098 11,605 57,118 39,668 Expenses: S,G&A 8,662 6,562 31,744 27,579 Research and Development 3,365 2,935 10,281 11,070 Amortization of other Intangible assets 968 1,147 3,776 4,725 Impairment of other Intangible assets 2,333 2,967 2,333 2,967 Restructuring Charges 394 1,602 Operating (Loss) Income 770 (2,400) 8,984 (8,275) Financial expenses 1,694 74 3449 2,907 Other income (26) (2) (212) (12) Taxes on income (58) (812) 1,054 2,402 Net Income (Loss) for the year (840) (1,660) 4,693 (13,572) PRNewswire-FirstCall -- March 3 DATASOURCE: Scitex Corporation Ltd.

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

SCIX Global X Scientific Beta Asia ex Japan ETF